Nodular lymphocyte-predominant Hodgkin lymphoma

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare Hodgkin lymphoma subtype with distinct histologic and clinical features compared to classic Hodgkin lymphoma (cHL).
• Prognosis for NLPHL in advanced stages mirrors that of cHL, necessitating similar treatment approaches.
• Early favorable-stage NLPHL exhibits a superior prognosis compared to cHL, suggesting potential for less intensive therapeutic strategies.

Purpose of the Study:

• To evaluate the potential for reduced-intensity treatment programs in early favorable-stage NLPHL without compromising cure rates.
• To review the established efficacy of involved-field radiotherapy as a primary treatment for stage IA NLPHL.
• To explore the emerging role of the monoclonal antibody rituximab in first-line NLPHL treatment.

Main Methods:

• Comparative analysis of prognostic data between NLPHL and cHL across different disease stages.
• Review of treatment outcomes for involved-field radiotherapy versus extended-field radiotherapy or combined modalities in early-stage NLPHL.
• Examination of clinical trial data investigating rituximab in relapsed and potentially first-line NLPHL.

Main Results:

• Early favorable-stage NLPHL demonstrates a significantly better prognosis than cHL.
• Involved-field radiotherapy is as effective as more extensive treatments for stage IA NLPHL and is the adopted standard by major study groups.
• Rituximab has demonstrated efficacy in relapsed NLPHL, prompting investigation into its first-line use.

Conclusions:

• Reduced-intensity treatment regimens are a viable consideration for early favorable-stage NLPHL, potentially improving patient quality of life.
• Involved-field radiotherapy is a highly effective and preferred treatment for stage IA NLPHL.
• Rituximab represents a promising avenue for first-line therapy in NLPHL, warranting further clinical investigation.